These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 6992450)
41. [Nucleic acids and their therapeutic use (review of the literature)]. Rychnev VE; Frolov VM Vrach Delo; 1981 Aug; (8):114-8. PubMed ID: 6168110 [No Abstract] [Full Text] [Related]
42. [Effects of 2 different antineoplastic agents on the intact and regenerated liver. Vincristine-peptichemio (experimental study in the rat). I]. Contieri E; Soscia A; Di Prisco B; Di Tuoro A; Iodice R; Belli F; Izzo R; Micheli P Chir Patol Sper; 1978 Feb; 26(1):33-43. PubMed ID: 743897 [No Abstract] [Full Text] [Related]
43. [The effect of pyrimidine derivatives on labeled amino acid incorporation into liver proteins]. Lifshits RI; Kamilov FKh Vopr Med Khim; 1972; 18(4):347-50. PubMed ID: 4661839 [No Abstract] [Full Text] [Related]
45. [Protein and nucleic acid metabolism in the liver during its pathologic regeneration]. Mirakhmedov MM; Shakirova RM; Khalikov SK Vopr Med Khim; 1974; 20(1):22-4. PubMed ID: 4454266 [No Abstract] [Full Text] [Related]
46. [Mechanism of the action of hepatoprotectors in toxic liver lesions]. Vengerovskiĭ AI; Saratikov AS Farmakol Toksikol; 1988; 51(1):89-93. PubMed ID: 3282917 [No Abstract] [Full Text] [Related]
47. The liver: a pharmacologic perspective. Bossone CM Nurs Clin North Am; 1977 Jun; 12(2):291-303. PubMed ID: 585856 [TBL] [Abstract][Full Text] [Related]
48. [Diagnostic value of determining ceruloplasmin and transferrin in various acute and chronic liver diseases]. Dzhalalov AD; Maksimov VA Ter Arkh; 1982; 54(2):57-9. PubMed ID: 7071774 [No Abstract] [Full Text] [Related]
49. [The effect of salt-alkaline and carbonated mineral waters on the protein-forming function of the liver in animals with experimental hepatitis]. Kudlaenko KI Vopr Kurortol Fizioter Lech Fiz Kult; 1968 Jan; 33(1):21-6. PubMed ID: 5742766 [No Abstract] [Full Text] [Related]
50. [Treatment of autoimmune hepatic diseases]. Bueverov AO Klin Med (Mosk); 2004; 82(10):62-6. PubMed ID: 15584604 [TBL] [Abstract][Full Text] [Related]
51. Albumin-drug conjugates in the treatment of hepatic disorders. Fiume L; Manerba M; Di Stefano G Expert Opin Drug Deliv; 2014 Aug; 11(8):1203-17. PubMed ID: 24773257 [TBL] [Abstract][Full Text] [Related]
52. Effect of rosuvastatin on cholestasis-induced hepatic injury in rat livers. Awad AS; Kamel R J Biochem Mol Toxicol; 2010; 24(2):89-94. PubMed ID: 20146376 [TBL] [Abstract][Full Text] [Related]
54. Copper: its role in the pathogenesis of liver disease. Walshe JM Semin Liver Dis; 1984 Aug; 4(3):252-63. PubMed ID: 6385272 [No Abstract] [Full Text] [Related]
55. [Ursodeoxycholic acid: an alternative in the treatment of chronic cholestasis]. Parés A; Rodés J Gastroenterol Hepatol; 1996 Feb; 19(2):58-67. PubMed ID: 8616682 [No Abstract] [Full Text] [Related]